单采血浆站名称：凤冈中生单采血浆站 执业许可证号：522731 采浆区域（范围）：凤冈县 业务项目：单采原料血浆 证券代码：600161 证券简称：天坛生物 公告编号：2023-044 北京天坛生物制品股份有限公司 关于所属浆站获得单采血浆许可证公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京天坛生物制品股份有限公司（以下简称"公司"）所属国药集团贵州血 液制品有限公司凤冈中生单采血浆站（以下简称"凤冈浆站"）于近日收到贵州 省卫生健康委员会签发的《单采血浆许可证》。现将主要信息公告如下： 北京天坛生物制品股份有限公司 2023 年 11 月 1 日 有效期限：自 2023 年 11 月 1 日至 2025 年 10 月 31 日止 凤冈浆站自本次取得《单采血浆许可证》之日起可正式采浆。凤冈浆站实现 采浆将有利于提升公司原料血浆供应能力，对公司长期发展具有积极作用。 特此公告。 ...

Financial Performance - The company's operating revenue for Q3 2023 reached CNY 1,331,040,672.40, representing a year-on-year increase of 30.23%[3] - Net profit attributable to shareholders for Q3 2023 was CNY 320,600,799.11, up 48.49% compared to the same period last year[3] - Basic earnings per share for Q3 2023 were CNY 0.19, a 48.49% increase year-on-year[3] - The diluted earnings per share also stood at CNY 0.19, reflecting the same growth rate of 48.49% compared to the previous year[3] - The company reported a significant increase in net profit attributable to shareholders after deducting non-recurring gains, which rose by 53.60% in Q3 2023[7] - Net profit for the first three quarters of 2023 was CNY 1,207,616,323.66, up 46.2% from CNY 825,898,699.96 year-on-year[15] - The total operating profit for Q3 2023 was -36,530,744.50 RMB, compared to -30,032,164.13 RMB in Q3 2022, indicating a decline of approximately 21.7%[27] - The company reported a total comprehensive income of -35,892,851.40 RMB for Q3 2023, compared to -30,047,917.55 RMB in Q3 2022, reflecting a decline of approximately 19.3%[28] Cash Flow - The net cash flow from operating activities for Q3 2023 surged to CNY 1,069,253,857.72, an increase of 471.18% year-on-year[3] - Cash flow from operating activities for the first three quarters of 2023 was CNY 4,974,086,029.35, significantly higher than CNY 2,994,120,449.21 in the same period of 2022[19] - The net cash flow from operating activities for Q3 2023 was CNY 2,341,139,295.54, a significant increase from CNY 952,360,053.85 in Q3 2022, representing a year-over-year growth of approximately 146%[20] - The net cash flow from financing activities was negative at CNY -286,927,962.83, worsening from CNY -224,534,230.52 in Q3 2022[21] - The company reported a net increase in cash and cash equivalents of CNY 1,154,179,204.70 for Q3 2023, compared to a decrease of CNY -614,192,649.78 in Q3 2022[21] - The cash flow from financing activities in Q3 2023 was 1,451,506,095.86 RMB, significantly higher than 253,407,116.59 RMB in Q3 2022, reflecting a growth of approximately 471.5%[30] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 14,596,788,026.70, reflecting a 12.80% increase from the end of the previous year[4] - Total liabilities as of the end of Q3 2023 amounted to CNY 2,117,371,560.17, an increase from CNY 1,584,369,943.88 at the end of Q3 2022[13] - Total equity attributable to shareholders reached CNY 9,600,750,278.56, compared to CNY 8,795,740,348.20 in the previous year[13] - The total assets as of September 30, 2023, amounted to CNY 7,547,882,024.14, an increase from CNY 6,097,398,088.57 at the end of 2022[24] - The total liabilities as of September 30, 2023, were CNY 2,356,649,399.82, compared to CNY 787,882,135.95 at the end of 2022, indicating a significant increase[25] Shareholder Information - The company has a total of 52,870 common shareholders as of the reporting date[10] - The largest shareholder, China Biotechnology Co., Ltd., holds 45.64% of the shares, totaling 752,083,740 shares[10] - The company has no pledged, marked, or frozen shares among the top shareholders[10] Operational Insights - The report indicates no significant changes in the company's operational strategies or new product developments during the quarter[11] - Research and development expenses for the first three quarters of 2023 were CNY 58,350,420.20, down from CNY 81,123,931.51 in the same period of 2022[14] - The total cost of operations for the first three quarters of 2023 was CNY 2,618,355,943.43, an increase from CNY 1,992,229,904.77 in the previous year[14] - Management expenses increased to CNY 67,961,600.88 in 2023 from CNY 62,844,993.75 in 2022, marking an increase of about 15%[26]

证券代码：600161 证券简称：天坛生物 公告编号：2023-043 北京天坛生物制品股份有限公司 同意公司所属国药集团兰州生物制药有限公司（以下简称"兰州血制"）全 额出资 1,300 万元增加永登兰生单采血浆有限责任公司（以下简称"永登浆站"） 注册资本，增资完成后，永登浆站注册资本由 2,700 万元增加至 4,000 万元，兰 州血制持有 100%的股权。增资款项由兰州血制自筹。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 第九届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司(以下简称"公司")第九届董事会第四次会 议于 2023 年 10 月 19 日以电子方式发出会议通知，于 2023 年 10 月 25 日以通讯 表决方式召开。会议应参加表决董事九人，实际参加表决董事九人。会议符合《公 司法》及《公司章程》的有关规定，会议审议通过以下议案： 一、审议通过《关于上海血制增资永德县上生单采血浆有限公司的议案》 同意公司所属国药集团上海血液制品有限公司 ...

证券代码：600161 证券简称：天坛生物 公告编号：2023-040 一、 增持主体基本情况 （一）增持主体：公司部分董事、监事、高级管理人员等合计11人 北京天坛生物制品股份有限公司 关于部分董事、监事、高级管理人员增持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增持计划情况：北京天坛生物制品股份有限公司（以下简称"公司"）部分董 事、监事和高级管理人员等合计 11 人（以下合并简称"增持主体"）计划通过上海证 券交易所交易系统集中竞价交易方式以自有资金增持公司无限售流通股 A 股股份，计 划合计增持金额不低于 5,750,000 元。增持计划实施期限：自 2023 年 9 月 1 日起 6 个月内。具体情况请详见公司于 2023 年 8 月 30 日发布的《关于董事、监事、高级管 理人员增持股份计划公告》（2023-035）。 增持实施进展：截止 2023 年 9 月 26 日，部分增持主体已实施本次股份增持计 划，合计增持公司股份 123,400 股，占公司总股本的 0.01 ...

证券代码：600161 证券简称：天坛生物 公告编号：2023-041 北京天坛生物制品股份有限公司 关于所属企业获得药品补充申请批准通知书并通过药品 GMP 符合性检查公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京天坛生物制品股份有限公司所属成都蓉生药业有限责任公司（以下简称"成都蓉 生"）于近日收到国家药品监督管理局签发的《药品补充申请批准通知书》，成都蓉生研制 的"静注人免疫球蛋白（pH4）"符合药品注册的相关要求。同时，成都蓉生相关生产场地 已通过药品 GMP 符合性检查，并获得了四川省药品监督管理局签发的《药品 GMP 现场检查 结果通知书》（川 2022119）。具体情况如下： 一、概况 （一）产品信息 | 产品 | | | 申报生产获 | | 注册 | 剂 | 研发 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 适应症 | 文件名称 | 得受理的时 间及受理号 | 规格 | 分类 | 型 | 投入 | | | 1.治疗原发性 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京天坛生物制品股份有限公司（以下简称"公司"）所属国药集团贵州血 液制品有限公司黎平中生单采血浆站（以下简称"黎平浆站"）于近日收到贵州 省卫生健康委员会签发的《单采血浆许可证》。现将主要信息公告如下： 证券代码：600161 证券简称：天坛生物 公告编号：2023-039 北京天坛生物制品股份有限公司 关于所属浆站获得单采血浆许可证公告 单采血浆站名称：黎平中生单采血浆站 执业许可证号：522730 采浆区域（范围）：黎平县 业务项目：单采原料血浆 有效期限：自 2023 年 9 月 13 日至 2025 年 9 月 12 日止 黎平浆站自本次取得《单采血浆许可证》之日起可正式采浆。黎平浆站实现 采浆将有利于提升公司原料血浆供应能力，对公司长期发展具有积极作用。 特此公告。 北京天坛生物制品股份有限公司 2023 年 9 月 14 日 ...

证券代码：600161 证券简称：天坛生物 公告编号：2023-038 北京天坛生物制品股份有限公司 关于召开 2023 年半年度业绩说明会公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 9 月 21 日(星期四)10:00-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 9 月 14 日(星期四)至 9 月 20 日(星期三)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 ttswdb@sinopharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 一、 说明会类型 （二） 会议召开地点：上海证券交易所上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 北京天坛生物制品股份有限公司（以下简称"公司"）已于 ...

关于所属企业获得药品注册证书并通过药品 GMP 符合性检查公告 证券代码：600161 证券简称：天坛生物 公告编号：2023-037 北京天坛生物制品股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京天坛生物制品股份有限公司所属成都蓉生药业有限责任公司（以下简称 "成都蓉生"）于近日收到国家药品监督管理局签发的《药品注册证书》，成都蓉生 研制的"注射用重组人凝血因子Ⅷ"符合药品注册的相关要求。同时，成都蓉生相 关生产场地已通过药品 GMP 符合性检查，并获得四川省药品监督管理局签发的《药 品 GMP 现场检查结果通知书》（川 2022100）。具体情况如下： 一、概况 （一）产品信息 | 产品 | | 适应症 | | 文件名称 | 申报生产获得受 理的时间及受理 | 规格 | 注册 | 剂 | 研发 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | | | | | 分类 | 型 | 投入 | | | | ...

机构名称：洪湖武生单采血浆站 许可证号：鄂卫采浆站字【2023】第 02 号 业务项目：采供原料血浆、特免血浆 采浆区域：洪湖市 有效期限：自 2023 年 9 月 4 日至 2025 年 9 月 3 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京天坛生物制品股份有限公司（以下简称"公司"）所属国药集团武汉血 液制品有限公司洪湖武生单采血浆站（以下简称"洪湖浆站"）于近日收到湖北 省卫生健康委员会签发的《单采血浆许可证》。现将主要信息公告如下： 洪湖浆站自本次取得《单采血浆许可证》之日起可正式采浆。洪湖浆站实现 采浆将有利于提升公司原料血浆供应能力，对公司长期发展具有积极作用。 特此公告。 2023 年 9 月 6 日 证券代码：600161 证券简称：天坛生物 公告编号：2023-036 北京天坛生物制品股份有限公司 关于所属浆站获得单采血浆许可证公告 北京天坛生物制品股份有限公司 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached approximately CNY 2.69 billion, representing a 42.34% increase compared to CNY 1.89 billion in the same period last year[18]. - Net profit attributable to shareholders for the first half of 2023 was approximately CNY 566.80 million, up 47.24% from CNY 384.95 million year-on-year[18]. - The net cash flow from operating activities increased by 66.23%, amounting to approximately CNY 1.27 billion compared to CNY 765.16 million in the previous year[18]. - The basic earnings per share for the first half of 2023 was CNY 0.34, a 47.24% increase from CNY 0.23 in the same period last year[18]. - The weighted average return on net assets rose to 6.24%, an increase of 1.56 percentage points from 4.68% in the previous year[18]. - The company achieved operating revenue of 2,690.96 million yuan, a year-on-year increase of 42.34%[36]. - The net profit attributable to shareholders reached 566.80 million yuan, reflecting a year-on-year growth of 47.24%[36]. - The company reported a total cash balance of CNY 3,748,523,040.00, accounting for 27.00% of total assets, which is relatively stable compared to the previous year[69]. - The company reported a total of 752,083,740 shares held by China Biotechnology Co., Ltd., representing 45.64% of total shares[146]. - The company reported a net increase in equity of 691,811,286 during the first half of 2023, reflecting strong financial performance[176]. Business Operations - The main business involves the research, production, and sales of blood products, with a focus on albumin, immunoglobulin, and coagulation factors[24]. - The company operates 102 plasma collection stations, with 76 currently operational and 26 under construction, maintaining a leading position in domestic plasma collection[33]. - The company has developed 14 types of blood products, including human albumin and immunoglobulin, maintaining a dominant market share in China[37]. - The company has established a comprehensive blood source management system, ensuring the quality and safety of plasma collection[41]. - The company has made significant investments in digitalization, enhancing production automation and management digitalization[48]. - The company has established a comprehensive quality management system for R&D, ensuring high standards throughout the product lifecycle[34]. - The company has implemented a centralized procurement strategy to reduce costs and improve efficiency[36]. - The company has completed clinical research for four new products, which are now in the registration application stage[53]. - The company has signed quality management responsibility agreements with 76 plasma collection stations, ensuring a 100% self-inspection and batch release qualification rate for its products[52]. Market and Industry Trends - The blood products industry in China is experiencing continuous market expansion, driven by the implementation of the Healthy China strategy and an increasing elderly population[24]. - There remains a significant gap in blood product consumption per capita compared to Western countries, indicating potential growth opportunities in the domestic market[24]. - The company is committed to expanding its market presence and enhancing its product portfolio through ongoing research and development efforts[25]. - The blood products are critical for national health security and are considered strategic materials in emergency medical situations[24]. - The company is actively expanding its market presence through government procurement and strategic partnerships[32]. Research and Development - The company emphasizes R&D, with over 100 researchers and advanced facilities, focusing on innovative blood products and technologies[34]. - The company focuses on high-concentration immunoglobulin and recombinant coagulation factor products, maintaining a leading position in R&D within the industry[39]. - The company has received nine authorized patents during the reporting period, including four invention patents[53]. - The company has implemented a research and development incentive plan to enhance the motivation and creativity of its research personnel, aiming to improve research progress and quality[94]. Environmental Responsibility - The company’s environmental management includes strict adherence to national standards for waste gas and wastewater discharge, ensuring compliance with pollution control regulations[100]. - The company reported a total hazardous waste disposal of 329.194 tons by Chengdu Rongsheng, 143.3105 tons by Shanghai Blood Products, and 15.211 tons by Kunming Blood Products, all of which were disposed of in compliance with regulations[100]. - The company has established an emergency response plan for environmental incidents to effectively prevent and control pollution events[117]. - The company has saved approximately 351,400 kWh of electricity during the reporting period as part of its energy conservation efforts[121]. Corporate Governance and Compliance - The company held its annual general meeting on May 25, 2023, where it approved the election of the ninth board of directors and the supervisory board[92]. - The company has undergone a board and supervisory board restructuring, with several new members elected as part of the governance changes[91]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[194]. - The financial statements comply with the requirements of the enterprise accounting standards, ensuring accurate reflection of financial status[196]. Related Party Transactions - The company commits to not using related party transactions to illegally transfer funds or profits from Tian Tan Biological, ensuring no harm to the interests of minority shareholders[133]. - The total amount of related party transactions reached CNY 6,295,998.38, with no significant returns reported[137]. - The company will strictly adhere to legal regulations and maintain the independence of Tian Tan Biological in assets, finance, personnel, business, and organization[133]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies[182]. - The company has set a future performance guidance indicating a growth target of 10% for the next fiscal year[182]. - The company plans to continue its focus on capital accumulation and shareholder returns in the upcoming periods[176].